Inspire Senior Vice President Receives Industrial Innovation Award For Product Advancements With P2Y2 Receptors.DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ISPH ISPH Inspire Pharmaceuticals, Inc. ) today announced that Benjamin R. Yerxa, Ph.D., Senior Vice President, Discovery at Inspire, received the Southeastern Region American Chemical Society The American Chemical Society (ACS) is a learned society (professional association) based in the United States that supports scientific inquiry in the field of chemistry. Founded in 1876 at New York University, the ACS currently has over 160,000 members at all degree-levels and in (ACS (Asynchronous Communications Server) See network access server. ) Industrial Innovation Award for discoveries related to his work with P2Y2 receptors. Specifically, ACS noted that Dr. Yerxa was recognized for his work in identifying the role that P2Y2 receptors play in tear secretion. He helped design and synthesize P2Y2 receptor agonists, including diquafosol tetrasodium for the treatment of dry eye, and led the development of this program through to its current stage. Dr. Yerxa is the lead inventor on four patents related to diquafosol tetrasodium composition and is named in 15 of Inspire's issued U.S. patents. "It is a great honor to have an Inspire team member recognized as a leader amongst the many innovative scientists and companies located in a region so heavily focused on science," said Christy L. Shaffer, Ph.D., Chief Executive Officer of Inspire Pharmaceuticals. "We congratulate Ben on receiving this prestigious award and recognize his tremendous contributions in developing the technologies and product pipeline that are key to Inspire's current and future success." Dr. Yerxa has served as Senior Vice President, Discovery since March 2003. He joined Inspire in August 1995 and has held several positions, including Vice President, Discovery and Senior Director of Preclinical Programs prior to his current appointment. He supervises the Chemistry, Biology and Intellectual Property teams, and all drug discovery and early preclinical development activities. Dr. Yerxa received his Ph.D. in Organic Chemistry from the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). , Irvine in 1993. The award was presented at a banquet held during SERMACS 2004 (Southeastern Regional Meeting of the American Chemical Society) from November 10-13, 2004 in Research Triangle Park Research Triangle Park, research, business, medical, and educational complex situated in central North Carolina. It has an area of 6,900 acres (2,795 hectares) and is 8 × 2 mi (13 × 3 km) in size. Named for the triangle formed by Duke Univ. , N.C. Initiated in 1998, the ACS Regional Industrial Innovation Awards Program has honored over 140 chemists from over 50 chemical companies for their invaluable contributions to their company and society. The program celebrates the successful innovations of industrial chemists and chemical engineers that contribute to the health of their local and regional economy and the corporate leadership for its advancement of a healthy economy. Awards are given to individuals and teams whose creative innovations have contributed to the commercial success of their company and, consequently, to the good of the community and society. About Inspire Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing novel prescription products for diseases with significant unmet medical needs. Inspire has significant technical and scientific expertise in the therapy areas of ophthalmology and respiratory and is a leader in the field of P2 receptors which are important drug targets in various therapeutic areas, including ophthalmology, respiratory disease Noun 1. respiratory disease - a disease affecting the respiratory system respiratory disorder, respiratory illness adult respiratory distress syndrome, ARDS, wet lung, white lung - acute lung injury characterized by coughing and rales; inflammation of the , cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease and pain. Inspire's specialty sales force promotes Elestat(TM) and Restasis(R), ophthalmology products developed by Inspire's partner, Allergan, Inc. Forward-Looking Statements The forward-looking statements in this news release relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc management's expectations and beliefs are based on preliminary information and management assumptions. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue and earnings expectations, intellectual property rights and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , competitive products, results of clinical trials, the need for additional research and testing, delays in manufacturing, funding and the timing and content of decisions made by regulatory authorities, including the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. . Further information regarding factors that could affect Inspire's results is included in Inspire's filings with the Securities and Exchange Commission. Inspire undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion